REG - Agronomics Limited - Final Results
27/12/2023 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231227:nRSa8390Xa&default-theme=true
RNS Number : 8390X Agronomics Limited 27 December 2023
27 December 2023
Agronomics Limited
("Agronomics" or the "Company")
Annual audited results for the year ending 30 June 2023
Notice of AGM
The Board of Agronomics, a leading listed investor in cellular agriculture, is
pleased to announce its annual results for the year ending 30 June 2023.
Copies of the 2023 Audited Report and Financial Statements are being posted to
shareholders and will shortly be available from the Company's website,
https://agronomics.im/investors/ (https://agronomics.im/investors/) , in the
investor portal section, under the financial reports tab.
The Company will post its Notice of Annual General Meeting ("AGM") to
Shareholders at the same time. The AGM will be held at the Sanderson Suite,
Claremont Hotel, Loch Promenade, Douglas, Isle of Man IM1 2LX at 10:00 a.m. on
8 February 2024.
The Board considers it important that all shareholders should have the
opportunity to exercise their voting rights at the AGM. To this end, the
Company invites shareholders to complete the voting proxy form as early as
possible. Shareholders may also submit questions to the Company Secretary
either in writing at the registered office or by email to katie@burnbrae.com
prior to the meeting and as early as possible.
Financial Highlights
· Net asset value per share (NAV) at 30 June 2023 of 16.94 pence (2022:
14.85 pence), an increase of 14%.
· Net operating profit of £25,746,348 (2022: £12,920,927) prior to
accounting for the Shellbay fee due of £3,372,672 (2022: £4,562,548)
· Net profit after taxation and the Shellbay fee of £22,373,676 (2022:
£8,358,379).
· Investment income, including net unrealised gains, reflected a gain
of £29,703,324 (2022: £6,423,869).
· The carrying amount of invested assets is £141,773,297 (2022:
£94,813,088), an increase of 49%
· Cash and cash equivalents and cash deposits stood at £28,093,984
(2022: £51,482,501).
· Total assets of £170,203,091 at 30 June 2023 (2022: £146,398,248).
· Total liabilities of £1,946,093 at 30 June 2023 (2022: £2,485,346),
including the cash portion of the Shellbay fee due of £1,686,336.
Operational Highlights
· Led four funding rounds including the Series A round of All G Foods,
the Seed round of UK-based fermentation company Clean Food Group, the Seed
round of contract manufacturer Liberation Labs, and the seed financing round
of HydGene Renewables Pty Ltd's, to engineer microorganisms for hydrogen
production.
· In August 2022, Agronomics led All G Food Holding Pty Ltd's (All G
Foods) AUD 25 million Series A Round with an AUD 15 million investment. All G
Foods is a precision fermentation company based in Australia focusing on the
production of sustainable dairy products and proteins.
· In August 2022, Agronomics led Clean Food Group Limited's (Clean Food
Group) seed financing with a £577,500 investment. Clean Food Group owns
intellectual property developed by the University of Bath for a technology
platform that produces a bio-equivalent palm oil alternative using microbial
fermentation.
· In October 2022, Agronomics announced a US$ 7million additional
investment into Liberation Labs Holdings as part of a US$ 20 million Seed
financing round. Agronomics precision fermentation contract manufacture
portfolio company, Liberation Labs, has made significant progress, including
selecting its first site in Richmond, Indiana, US, for its 600,000-litre
capacity commercial plant.
· In February 2023, Agronomics announced a US$ 500,000 investment in
Wild Microbes Company's (Wild Microbes) US$ 3.3 million pre-seed financing.
The company has proprietary technology that allows it to genetically engineer
novel microbial strains for use as host organisms to produce proteins and
other valuable molecules.
· In June 2023, Agronomics announced a AUD 2.5 million investment in
HydGene Renewables Pty Ltd's (HydGene). HydGene engineer's microorganisms act
as a proprietary biocatalyst for the production of green hydrogen. The
catalyst enables the conversion of waste biomass into gases such as hydrogen
and ammonia.
Post-period End Highlights
· During the post-period, the United States Department of Agriculture
("USDA") awarded Ameris Bancorp ("Ameris Bank") a US$ 25 million "Business and
Industry" loan guarantee to help the continued build and the completion of
Liberation Labs manufacturing facility.
· Agronomics invested €4 million as part of Meatable's €30 million
Series B financing round to help further scale Meatable's production processes
and accelerate its commercial programme in target markets to deliver
cultivated meat products that are price competitive with traditional meat.
· Portfolio company BlueNalu, Inc. raised US$ 33.5 million from new and
existing investors in a Series B round. The financing will enable the next
stage of BlueNalu's growth and its continued progress towards scaling and
commercializing healthy and sustainable seafood in the U.S. and around the
world. BlueNalu plans to launch its first commercial product, premium bluefin
tuna toro, following regulatory approval. Agronomics has invested, in
aggregate, US $8 million across BueNalu's various funding rounds.
Jim Mellon, Chairperson of Agronomics Limited, commented:
"This financial year has been another strong year of growth for Agronomics and
has seen significant progress made across our diverse portfolio within the
field of cellular agriculture. We have made investments in new and existing
portfolio companies across three main areas; cultivated meat and material,
precision fermentation and enabling technologies.
Our conservative valuation methodology leads us to believe that there is
significant intrinsic value within our portfolio, and we remain well
positioned to identify attractive opportunities in the sector. Agronomics has
maintained its strong cash position to ensure reserves to support existing
portfolio companies where we have high levels of conviction. However, we have
also participated in select new deals as investment and commercial progress
continues to develop across the sector. We recognise the persistent market
turmoil and whilst this reflects the wider macroeconomic environment, we
maintain our optimism for the cellular agriculture field.
During the year, the industry also made significant progress and saw the first
approval of cultivated meat product in the US by the FDA and USDA. This was a
landmark event for the field of cultivated meat and moves us further along the
path to full scale commercialisation. We look forward to further approvals
from within Agronomics' leading portfolio of companies and we expect to start
seeing regulatory approvals across our portfolio in major protein categories
from 2024.
The portfolio continues to show great robustness in the market downturn, as
shown by the number of funding rounds that continue to be achieved with
uplifts. We have to address the nature of venture capital, and the likelihood
of sector consolidation in the near term, as category leaders are identified.
We believe our current investment portfolio contains many of these category
leaders and shows considerable promise for future growth, particularly given
the scale of opportunity for the cellular agriculture sector. The Board will
also continue to seek new opportunities in line with its Investing Policy, and
we look forward to the future with confidence."
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET
ABUSE REGULATION (EU No. 596/2014) AS IT FORMS PART OF UK DOMESTIC LAW BY
VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF
THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE
INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN AND SUCH PERSONS
SHALL THEREFORE CEASE TO BE IN POSSESSION OF INSIDE INFORMATION.
For further information please contact:
Agronomics Beaumont Canaccord Cavendish Capital Markets Limited Peterhouse Capital
Limited Cornish Limited Genuity Limited Limited SEC Newgate
The Company Nomad Joint Broker Joint Broker Joint Broker Public Relations
Jim Mellon Roland Cornish Andrew Potts Giles Balleny Lucy Williams Bob Huxford
Denham Eke Jim Biddle Harry Pardoe Alex Aylen George LawsonMichael Johnson Charles Goodfellow George Esmond
(Head of Equities)
+44 (0) 1624 639396 +44 (0) 207 628 3396 +44 (0) 207 397 8900 +44 (0) 207 469 0936 Agronomics@secnewgate.co.uk (mailto:Agronomics@secnewgate.co.uk)
info@agronomics.im (mailto:info@agronomics.im) +44 (0) 207 523 8000
Chairman's statement
I am pleased to present the Annual Report for Agronomics Limited ("Agronomics"
or the "Company") for the year ended 30 June 2023.
This financial year, Agronomics has maintained its strong cash position to
ensure reserves to support existing portfolio companies where we have high
levels of conviction. However, we have also participated in select new deals
where we see companies making strong investment and commercial progress across
the sector. We recognise the challenging market conditions and whilst this
reflects the wider macroeconomic environment, we maintain our optimism for the
cellular agriculture field. The technologies into which we have invested have
the potential to revolutionise the production of key food products such as
proteins, fats, eggs, coffee, cocoa and meat, and have wider applications to
the materials and energy industries.
We are in an era where investment opportunities should offer a positive impact
on society, in addition to providing attractive risk-adjusted returns.
Cellular agriculture technologies have the potential to achieve that by
contributing to the decarbonisation of the world's key production systems
while being a critical technology to support food security. . These
technologies include cell culture - harnessing stem cells to produce meat,
without the slaughter of the animal; and precision fermentation - utilising
microbes as cell factories to produce targeted valuable ingredients, such as
dairy and egg proteins. All of these technologies only have validity if the
products can achieve parity with their conventional counterparts, not only in
terms of price but also sensory profile and convenience.
We have seen successful progress across the portfolio this year. Post period
end cultivated seafood producer BlueNalu, of which we own 5.12%, signed an MoU
with NEOM, entering a strategic partnership to progress the commercialisation,
marketing, and distribution of its cell-cultured seafood products. The NEOM
Investment Fund also led Blue Nalu's $35m Series B round with a US $20 million
investment. These developments exemplify the demand for cellular agriculture
as food insecurity continues to rise across the globe, and climate change and
the fragility of supply chains persist.
In a world retreating from globalisation, there is an increasing need for
localised and secure supply chains. As the financial firm Boston Consulting
Group reported, "As highlighted by the recent pandemic, and the ongoing
conflict in Europe, as well as natural disasters around the world, the
vulnerability of global supply chains has only risen over time". This ties
into the US' announcement of the National Biotechnology and Biomanufacturing
Initiative in September 2022, to focus on expanding domestic biomanufacturing
and fostering local innovation.
Therefore, within the year, we have focused resources on supporting the launch
of our precision fermentation contract manufacturer, Liberation Labs to
provide capacity for industrial-scale production. As key backers of this
business, alongside the leading experts in facility design and execution, Mark
Warner and Etan Bendheim, we have committed to driving this business forward.
In this period, Liberation Labs made significant progress, including selecting
its first site in Richmond, Indiana, US, for its 600,000 litre capacity
commercial plant.
Liberation Labs broke ground during the summer, and the build is on track to
be completed in Q1 2025 when it will host its first precision fermentation
customers. There continues to be a lack of fermentation capacity as the new
wave of applications of biomanufacturing enters commercialisation. Today
there are approximately 61 million litres of operating bioreactor capacity
worldwide, and according to projections from Boston Consulting Group, 15
megatonnes of animal protein will be produced via microbes by 2030 which will
require 100x the current capacity. Liberation Labs has a clear leadership
position in the expansion of this capacity, yet is adding only 1% capacity as
legacy facilities, particularly in Europe, approach the end of their economic
life. Liberation Labs is the only contract manufacturer dedicated to building
fit-for-purpose industrial-scale precision fermentation plants and Agronomics
currently owns 37.4% of Liberation Labs.
During the financial year, we expanded our precision fermentation exposure,
recognising the addition of Hydgene to the portfolio, leveraging microbes to
convert biomass waste into hydrogen and ammonia. We led the Series A of All G
Foods, which is focused on producing high-value lactoferrin and casein dairy
proteins from microbes. Both of these companies are based in Australia,
highlighting the increased geographic diversification of the portfolio. We
further participated in the Seed round of Wild Microbes, focused on expanding
the library of host organisms that can be used in precision fermentation, our
second investment in the 'enabling technology' category for the sector.
This financial year also saw the first regulatory approvals for cultivated
meat in the US with the ground-breaking achievements of Upside Foods and Good
Meat as the first companies to receive approval under the joint regulatory
framework of the US FDA and USDA. Both of these companies gained approval for
cultivated chicken and have been serving their products in restaurants. We see
these approvals as the first of several expected in 2024. Within our
portfolio, we continue to believe our companies have the best technologies to
achieve optimal productivity and favourable unit economics and become category
leaders for the respective products. This is showcased by our support for
Meatable, and why we led their EUR 30 million Series B funding round. This
investment is expected to enable Meatable to leverage its unique access to the
opti-oxTM technology, allowing for an efficient bioprocess as it looks to
commercialise its pork and beef products in a capital-efficient manner. Within
the portfolio, Solar Foods received its first novel food regulatory approval
in Singapore for the commercialisation of its protein Solein, grown using
carbon dioxide and electricity.
We maintain our expectation that regulatory approvals for our portfolio
companies will continue in 2024 in key jurisdictions such as the US and
Singapore.
Agronomics has cash and deposits as at 30 June 2023 of £28.1 million,
following its successful fundraises during 2021, and it has maintained a
healthy balance sheet to pursue follow-on opportunities within the portfolio
as well as continue to target new and unique deals within the field of
cellular agriculture.
The portfolio continues to show great robustness in the market downturn, as
shown by the number of portfolio company funding rounds that continue to be
achieved with price uplifts. We have to address the nature of venture capital,
and the likelihood of sector consolidation in the near term, as category
leaders are identified. We continue to believe we hold a number of these in
our portfolio, with companies suitably adjusting their cash burns and runways
to survive the market downturn.
Both cell culturing and precision fermentation technologies only have mass
market validity if companies can prove the technologies can become cheap
enough to compete, on a unit economic, taste, and nutrition basis, with
conventional proteins or ingredients. We have high conviction that our
portfolio companies have the toolset and technologies to scale their products
to mass markets at prices competitive to conventional agriculture.
Details regarding principal risks and uncertainties that apply to the Company
can be found in Note 8.
Investment Review
During the financial year, Agronomics made several investments in new and
existing portfolio companies. In the first half it led three funding rounds
including the Series A round of All G Foods, the Seed round of UK-based
fermentation company Clean Food Group, and the Seed round of contract
manufacturer Liberation Labs.
In the second half of the financial year, Agronomics led HydGene's AUD 6
million Seed financing round with an AUD 2.5 million investment, to engineer
microorganisms for hydrogen production. The Company also participated in the
Wild Microbes US$ 3.3 million pre-seed financing round, with a US$ 500k
investment, to identify novel microbial strains for use as cell factories to
produce valuable molecules. Post 30 June 2023 year end, Agronomics
successfully led the US$ 30 million Series B financing round of existing
portfolio company Meatable, harnessing cell culture to produce cultivated beef
and pork with its unique opti-oxTM technology.
The full commentary on the activities for the financial year can be found
below.
On 1 August 2022, Agronomics led portfolio company Clean Food Group Limited's
(Clean Food Group) seed financing round with a £577,500 investment
subscribing for 5,775,000 additional Ordinary Shares bringing Agronomics
equity stake to 35.03% and an aggregate value of £3,807,500. This follows
Agronomics' first subscription of £323,000 for 32,300,000 shares of the
company in March 2022. Clean Food Group acquired the intellectual property for
a technology platform that produces bio-equivalent palm oil using microbial
fermentation from the University of Bath. Clean Food Group subsequently
secured a two-year collaboration to scale the technology and support launching
their palm oil product to market.
On 4 August 2022, Agronomics announced it led All G Food Holding Pty Ltd's
(All G Foods) AUD 25 million Series A Round with an AUD 15 million investment,
subscribing for 2,803,214 Series A Preferred Shares. All G Foods is a
precision fermentation company based in Australia focusing on the production
of sustainable dairy products and proteins. Agronomics identified All G Foods
as having leading precision fermentation dairy expertise, most notably in its
focus on casein micelle formation which is critical for the full functionality
of dairy products and has posed a noticeable challenge for the sector
globally. Following the close of this round, Agronomics owns 9.35% of the
company on a fully diluted basis.
On 20 October 2022, Agronomics announced a US$ 7 million investment into
Liberation Labs Holdings Inc (Liberation Labs) in the form of an unconditional
subscription agreement. The investment was made in two tranches, the first of
which took place on 20 October 2022 and the second half in December 2022.
Liberation Labs was founded to address the critical shortage in precision
fermentation capacity for the production of proteins in food through the
construction of its first 600,000-litre launch facility in Richmond Indiana.
The proceeds from this funding round were used primarily to finalise its site
selection, complete pre-construction engineering, order long-lead equipment,
and continue to build out its team. Agronomics made its first investment in
Liberation Labs's Founding round in June 2022 in which it invested US$ 627,000
which is now carried at a 24.23x uplift. Agronomics' whole position is now
carried at an aggregate value of US$ 22.4 million with an unrealised gain of
$14.8 million.
On 23 February 2023, Agronomics announced a $500k investment in the form of a
Simple Agreement for Future Equity ("SAFE") in Wild Microbes Company's (Wild
Microbes) US$ 3.3 million pre-seed financing. The company has proprietary
technology that allows it to genetically engineer novel microbial strains for
use as host organisms to produce proteins and other valuable molecules. Since
the beginning of microbial engineering, the industry has been choosing host
cells from the same small handful of established and proven microorganisms.
Wild Microbes intends to create a catalogue mapping out the qualities and
characteristics of superior microorganisms which can significantly improve the
efficiency and productivity of host-cells. By identifying superior organisms,
yields can be increased which will bring down production costs, thus helping
precision fermentation companies to reach positive unit economics. The SAFE
will convert into preferred shares in a future qualified financing after which
Agronomics will own approximately 3.60% of the company on a fully diluted
basis.
On 15 June 2023, Agronomics announced a AUD 2.5 million investment in HydGene
Renewables Pty Ltd's (HydGene), AUD 6 million seed round for a 12.5% equity
stake in the company. HydGene engineers microorganisms to act as a proprietary
biocatalyst for the production of green hydrogen. The catalyst (produced via
fermentation) enables the conversion of waste biomass into gases such as
hydrogen and ammonia. With the majority of hydrogen currently being derived
from fossil fuels, HydGene's biocatalyst technology provides a unique
decentralised solution that reduces infrastructure requirements and costs. If
derived from a cost-effective, sustainable source, hydrogen could become a
mainstream supply of energy and could constitute 18% of the global energy
supply, becoming a $2.5 trillion global market by 2050.
At 30 June 2023, the following investments are held by the Company:
Financial Review
The Company recorded a net operating profit of £25,746,348 for the year
(2022: £12,920,927) prior to accounting for the fee due to Shellbay
Investments Limited ("Shellbay"). Taking into account a fee of £3,372,672
(2022: £4,562,548) due to Shellbay, the Company recorded a net profit after
taxation of £22,373,676 (2022: £8,358,379). Our investment income, including
net unrealised gains, reflected a gain of £29,703,324 (2022: £6,423,869).
Unrealised foreign exchange losses of £3,364,673 (2022: gains of £6,513,031)
have been recognised in profit and loss.
The carrying amount of invested assets is £141,773,297 (2022: £94,813,088),
an increase of 49%, and cash and equivalents and bank deposits stood at
£28,093,984 (2022: £51,482,501). Our total assets stood at £170,203,091
(2022: £146,398,248). Total liabilities stood at £1,946,093 (2022:
£2,485,346), which includes the cash portion of the Shellbay fee due of
£1,686,336. As a result, the net asset value per share at 30 June 2023 was
16.94 pence (2022: 14.85 pence), an increase of 14%.
Financing activity
During the year, the Company received warrant exercise notices and issued a
total of 947,405 Ordinary Shares, for cash proceeds of £284,060.
Strategy and Outlook
Our current investment portfolio shows considerable promise for future growth
given the scale of opportunity to invest in the cellular agriculture sector,
and the Board will continue to seek new opportunities in line with its
Investing Policy, details of which can be found on the Company website -
https://agronomics.im/investors/ (https://agronomics.im/investors/) .
Jim Mellon
Executive Chairperson
21 December 2023
Directors' report
The Directors of Agronomics Limited (the "Company") take pleasure in
presenting the Directors' report and financial statements for the year ended
30 June 2023.
Principal activity
Agronomics Limited is a Company domiciled in the Isle of Man. The Company's
strategy is to create value for Shareholders through investing in companies
that operate in the nascent industry of cellular agriculture, which are
environmentally friendly alternatives to the traditional production of meat
and plant-based sources.
Further details of the investing policy can be found on the Company's website
at www.agronomics.im (http://www.agronomics.im) .
Results and transfer to reserves
The results and transfers to reserves for the year are set out on pages 21 and
23.
The Company recorded a net operating profit of £25,746,348 for the year
(2022: £12,920,927) prior to accounting for the fee due to Shellbay
Investments Limited ("Shellbay"). Taking into account a fee of £3,372,672
(2022: £4,562,548) due to Shellbay, the Company recorded a net profit after
taxation of £22,373,676 (2022: £8,358,379).
The net asset value per share at 30 June 2023 was 16.94 pence (2022: 14.85
pence).
Dividend
The Directors do not propose the payment of a dividend (2022: £nil).
Policy and practice on payment of creditors
It is the policy of the Company to agree appropriate terms and conditions for
its transactions with suppliers by means of standard written terms to
individually negotiated contracts. The Company seeks to ensure that payments
are always made in accordance with these terms and conditions.
Financial risks
Details relating to the financial risk management are set out in note 8 to the
financial statements.
Directors
The Directors who served during the year and to date were:
Jim Mellon Executive Chairperson (appointed as Chairperson on 14 December 2023)
Denham Eke Executive Finance Director
Richard Reed Independent Non-Executive (resigned as Chairperson on 14 December 2023)
David Giampaolo Independent Non-Executive
Marisa Drew Independent Non-Executive
Directors' interests
As at 30 June 2023, the interests of the Directors and their families (as such
term is defined in the AIM Rules for Companies) in the share capital of the
Company are as follows:
Ordinary shares
30 June 2023 30 June 2022
Jim Mellon (1) 154,553,366 149,145,611
Denham Eke (2) 739,390 213,445
Richard Reed 6,354,412 6,354,412
David Giampaolo 2,434,783 2,434,783
1 - Galloway Limited, a company where Jim Mellon is considered to be the
ultimate beneficial owner, holds 139,448,641 shares and 12,722,764 are held
by Shellbay Investments Limited, companies which are both indirectly wholly
owned by Jim Mellon, and 2,381,961 Ordinary Shares are held directly by Mr
Mellon.
(2) - Denham Eke is Managing Director of Galloway Limited.
Significant shareholdings
Except for the interests disclosed in this note, the Directors are not aware
of any holding of ordinary shares as at 30 June 2023 representing 3% or more
of the issued share capital of the Company:
Number of Percentage of total
ordinary shares issued capital
Jim Mellon (1) 154,553,366 15.56%
Nutraco Nominees Limited 41,366,455 4.16%
Hargreaves Lansdown (Nominees) 40,579,646 4.09%
Chase Nominees Limited 39,239,575 3.95%
HSBC Global Custody Nominee (UK) 35,000,000 3.52%
Note:
1 - Galloway Limited, a company where Jim Mellon is considered to be the
ultimate beneficial owner, holds 139,448,641 shares and 12,722,764 are held
by Shellbay Investments Limited, companies which are both indirectly wholly
owned by Jim Mellon, and 2,381,961 ordinary shares are held directly by Mr
Mellon.
Auditors
KPMG Audit LLC, being eligible, have expressed their willingness to continue
in office.
On behalf of the Board
Denham Eke
Finance
Director
21 December 2023
1st Floor, Viking House
St Paul's Square
Ramsey, Isle of Man
IM8 1GB
Corporate Governance Statement
Corporate Governance Report
The Board of Agronomics (the "Board") is committed to best practice in
corporate governance throughout the Company (the "Company"). The Directors
have agreed to comply with the provisions of the Quoted Companies Alliance
("QCA") Corporate Governance Code for Small and Mid-Size Quoted Companies
(2018) to the extent which is appropriate to its nature and scale of
operations. This report illustrates how the Company complies with those
principles.
QCA Principle 1: Establish a strategy and business model which promotes
long-term value for shareholders
The strategy and business operations of the Company are set out in the
Chairman's Statement on pages 2 to 5.
The Company's strategy and business model and amendments thereto are developed
by the Chairperson and their senior management team and approved by the Board.
The management team is responsible for implementing the strategy and managing
the business at an operational level.
The Company's overall strategic objective is to develop a profitable and
sustainable platform for investing in the nascent industry of modern foods
which are environmentally friendly alternatives to the traditional production
of meat and plant-based sources of nutrition.
In executing the Company's strategy and operational plans, management will
typically confront a range of day-to-day challenges associated with these key
risks and uncertainties and will seek to deploy the identified mitigation
steps to manage these risks as they manifest themselves.
QCA Principle 2: Seek to understand and meet shareholder needs and
expectations
The Company via the Chairperson seeks to maintain a regular dialogue with both
existing and potential new shareholders in order to communicate the Company's
strategy and progress and to understand the needs and expectations of
shareholders.
Beyond the Annual General Meeting, the Chairperson and, where appropriate,
other members of the senior management team or Board will meet with investors
and analysts to provide them with updates on the Company's business and to
obtain feedback regarding the market's expectations of the Company.
The Company's investor relations activities encompass dialogue with both
institutional and private investors. From time to time, the Company attends
private investor events, providing an opportunity for those investors to meet
with representatives from the Company in a more informal setting.
QCA Principle 3: Take into account wider stakeholder and social
responsibilities and their implications for long-term success
The Company is aware of its corporate social responsibilities and the need to
maintain effective working relationships across a range of stakeholders. These
include the Company's advisors, suppliers, and investee companies. The
Company's operations and working methodologies take account of the need to
balance the needs of all these stakeholders while maintaining focus on the
Board's primary responsibility to promote the success of the Company for the
benefit of its members as a whole. The Company endeavours to take account of
feedback received from stakeholders, and where appropriate, ensures any
amendments are consistent with the Company's longer-term strategy.
The Company takes due account of any impact that its activities may have on
the environment and seeks to minimise this impact wherever possible.
QCA Principle 4: Embed effective risk management, considering both
opportunities and threats, throughout the organisation
The Board is responsible for the systems of risk management and internal
control and for reviewing their effectiveness. Internal controls are designed
to manage rather than eliminate risk and provide reasonable but not absolute
assurance against material misstatement or loss. Through the activities of the
Company Audit, Risk and Compliance Committee, the effectiveness of these
internal controls is reviewed annually.
A comprehensive budgeting process is completed once a year and is reviewed and
approved by the Board. The Company's results, compared with the budget, are
reported to the Board on a monthly basis.
The Company maintains appropriate insurance cover in respect of actions taken
against the Directors because of their roles, as well as against material loss
or claims against the Company. The insured values and type of cover are
comprehensively reviewed on a periodic basis.
The senior management team meets at least monthly to consider new risks and
opportunities presented to the Company, making recommendations to the Board
and/or Company Audit, Risk and Compliance Committee as appropriate.
QCA Principle 5: Maintain the board as a well-functioning, balanced team led
by the chair
The Company's Board currently comprises two Non-executive Directors and two
Executive Directors.
All of the Directors are subject to election by shareholders at the first
Annual General Meeting after their appointment to the Board and will continue
to seek re-election at least once every three years.
The Board is responsible to the shareholders for the proper management of the
Company and intends to meet at least four times a year to set the overall
direction and strategy of the Company, to review operational and financial
performance and to advise on management appointments. All key operational
decisions are subject to Board approval.
Richard Reed, David Giampaolo and Marisa Drew, all Non-executive Directors,
are considered to be independent. The QCA Code suggests that a board should
have at least two independent Non-executive Directors. The Board considers
that the current composition and structure of the Board of Directors is
appropriate to maintain effective oversight of the Company's activities for
the time being.
Non-executive Directors receive their fees in the form of a basic cash
emolument. The current remuneration structure for the Board's Executive and
Non-executive Directors is deemed to be proportionate.
QCA Principle 6: Ensure that between them the Directors have the necessary
up-to-date experience, skills, and capabilities
The Board considers that the Executive Directors and Non-executive Directors
are of sufficient competence and calibre to add strength and objectivity to
its activities and bring considerable experience in the operational and
financial development of the Company.
The Directors' biographies are detailed on the Company's website
www.agronomics.im (http://www.agronomics.im) .
The Board regularly reviews the composition of the Board to ensure that it has
the necessary breadth and depth of skills to support the ongoing development
of the Company.
The Chairperson, in conjunction with the Finance Director, ensures that the
Directors' knowledge is kept up to date on key issues and developments
pertaining to the Company, its operational environment and to the Directors'
responsibilities as members of the Board. During the course of the year,
Directors received updates from the Finance Director and various external
advisers on a number of corporate governance matters.
Directors' service contracts or appointment letters make provision for a
Director to seek professional advice in furtherance of his or her duties and
responsibilities, normally via the Company Secretary.
QCA Principle 7: Evaluate board performance based on clear and relevant
objectives, seeking continuous improvement
Internal evaluation of the Board, the Committees and individual Directors is
undertaken on an annual basis in the form of peer appraisal and discussions to
determine their effectiveness and performance as well as the Directors'
continued independence.
The results and recommendations that come out of the appraisals for the
Directors shall identify the key corporate and financial targets that are
relevant to each Director and their personal targets in terms of career
development and training. Progress against previous targets is also assessed
where relevant.
QCA Principle 8: Promote a corporate culture that is based on ethical values
and behaviours
The Board seeks to maintain the highest standards of integrity and probity in
the conduct of the Company's operations. With the Company being a vehicle for
holding investment, it has no employees and limited capacity to effect changes
in culture in companies it is affiliated with. However, the Board will strive
to ensure that the Company's in which it has an interest in, act in an ethical
manner.
The Board ensures that all portfolio companies have policies in place to
comply with applicable governance laws and regulations, such as anti-bribery
and modern-day slavery.
The Board has a zero-tolerance approach to breaches of these laws and
regulations. The Board promotes ethical behaviour throughout the portfolio,
through directions to the Company's investment advisors in relation to the
ethical management of the portfolio.
QCA Principle 9: Maintain governance structures and processes that are fit for
purpose and support good decision- making by the board
The Role of the Board
The Board is collectively responsible for the long-term success of the
organisation. Its principal function is to determine the strategy and policies
of the Company within an effective control framework which enables risk to be
assessed and managed.
The Board ensures that the necessary financial and human resources are in
place for the Company to meet its objectives and that business and management
performance is reviewed. Furthermore, the Board ensures that the Company
operates within its constitution, relevant legislation and regulation and that
proper accounting records and effective systems of business control are
established, maintained, documented, and audited.
There are at least four formal Board meetings each year. All Board members
have the benefit, at the Company's expense, of liability insurance in respect
of their responsibilities as Directors and have access to independent legal or
other professional advice if required. The Board has a formal schedule of
matters which are reserved for its consideration, and it has established three
committees to consider specific issues in greater detail, being the Company
Audit, Risk and Compliance, Remuneration and Nomination Committees. The Terms
of Reference for each of these Committees are published on the Company's
website.
The Chairperson
The Chairperson is responsible for leading the Board, ensuring its
effectiveness in all aspects of its role, promoting a culture of openness of
debate, and communicating with the Company's members on behalf of the Board.
The Chairperson sets the direction of the Board and promotes a culture of
openness and debate by facilitating the effective contribution of
Non-executive Directors and ensuring constructive relations between Executive
and Non-executive Directors. The Chairperson also ensures that Directors
receive accurate, timely and clear information. In doing so, this fosters a
positive corporate governance culture throughout the Company.
The Chief Executive Officer
At present, the Company does not have a Chief Executive Officer. Instead, the
responsibility for managing the Company's business and operations within the
parameters set by the Board is held by the Finance Director.
Non-executive Directors
The Non-executive Directors are responsible for bringing independent judgement
to the discussions held by the Board, using their breadth of experience and
understanding of the business. Their key responsibilities are to
constructively challenge and contribute to strategic proposals, and to monitor
performance, resources, and standards of conduct, compliance and control,
whilst providing support to executive management in developing the Company.
The Board has established a Company Audit, Risk and Compliance Committee
("ARCC"), a Remuneration Committee and a Nominations Committee with formally
delegated duties and responsibilities. Richard Reed chairs the ARCC, Jim
Mellon chairs the Remuneration Committee, and the Nominations Committee is
chaired by Richard Reed and comprised of the whole board.
Company Audit, Risk and Compliance Committee
The Company Audit, Risk and Compliance Committee meets at least two times each
year is chaired by Richard Reed. The external auditors attend by invitation.
Its role is to be responsible for reviewing the integrity of the financial
statements and the balance of information disclosed in the accompanying
Directors' Report, to review the effectiveness of internal controls and risk
management systems and recommend to the Board (for approval by the members)
the appointment or re-appointment of the external auditor. The ARCC reviews
and monitors the external auditor's objectivity, competence, effectiveness and
independence, ensuring that if it or its associates are invited to undertake
non-audit work it will not compromise auditor objectivity and independence.
Further information can be found within the Company Audit, Risk and Compliance
Report contained within this Annual Report.
Remuneration Committee
The Remuneration Committee intends to meet at least once a year and comprises
of two Non-executive Directors and one Executive Director. It is chaired by
Jim Mellon and is responsible for determining the remuneration of the
Executive Director, the Company Secretary and other members of the management.
Committee members do not take part in discussions concerning their own
remuneration.
Further information can be found within the Remuneration Report contained
within this Annual Report.
Nomination Committee
The Nomination Committee is comprised of the whole Board. It is chaired by the
Chairperson of the Board and is responsible for making recommendations to the
Board on matters relating to the composition of the Board, including Executive
and Non-executive Director succession planning, the appointment of new
Directors and the election and re-election of Directors. The Nomination
Committee only meets as matters arise.
Appointments to the Board
The principal purpose of the Nomination Committee is to undertake the
assessment of the balance of skills, experience, independence and knowledge on
the Board against the requirements of the business, with a view to determining
whether any shortages exist. Having completed the assessment, the Committee
makes recommendations to the Board accordingly. Appointments to the Board are
made on merit, with due regard to the benefits of diversity. Within this
context, the paramount objective is the selection of the best candidate,
irrespective of background, and it is the view of the Board that establishing
quotas or targets for the diversity of the Board is not appropriate.
All Director appointments must be approved by the Company's Nominated Adviser,
as required under the AIM Rules, before they are appointed to the Board.
Prior to appointment, Non-executive Directors are required to demonstrate that
they are able to allocate sufficient time to undertake their duties.
Re-election
The Company's Rules require that all Directors are submitted for election at
the AGM following their first appointment to the Board. Thereafter all
directors will submit themselves for re-election at least once every three
years, irrespective of performance.
Board and committee attendance
The number of formal scheduled Board and committee meetings held and attended
by Directors during the year was as follows: -
Board ARCC Nomination Remuneration
Richard Reed 19/19 2/2 1/1 1/1
David Giampaolo 19/19 2/2 1/1 0/1
Jim Mellon 19/19 - 1/1 1/1
Denham Eke 19/19 2/2 1/1 -
Marisa Drew* 6/19 - - -
* joined the Board on 23 February 2023.
QCA Principle 10: Communicate how the company is governed and is performing by
maintaining a dialogue with shareholders and other relevant stakeholders
The Company places a high priority on regular communications with its various
stakeholders and aims to ensure that all communications concerning the
Company's activities are clear, fair, and accurate. The Company's website is
regularly updated, and users can register to be alerted when announcements or
details of presentations and events are posted onto the website.
Notices of General Meetings of the Company can be found here:
https://agronomics.im/latest-news/ (https://agronomics.im/latest-news/) .
The results of voting on all resolutions in general meetings are posted to the
Company's website, including any actions to be taken as a result of
resolutions for which votes against have been received from at least 20 per
cent of independent shareholders.
Approval
This report was approved by the Board of Directors on 21 December 2023 and
signed on its behalf by:
Denham Eke
Finance Director
Audit, Risk and Compliance Committee Report
The Directors ensure the Company complies with the provisions of the Quoted
Companies Alliance ("QCA") Corporate Governance Code for Small and Mid-Size
Quoted Companies (2018) to the extent which is appropriate to its nature and
scale of operations.
This report illustrates how the Company complies with those principles in
relation to its Audit, Risk and Compliance Committee (the "ARCC").
Membership
The Committee comprises of two Non-Executive Directors, being Richard Reed and
David Giampaolo, and one Executive Director, being Denham Eke. The composition
of the Committee has been reviewed during the year and the Board is satisfied
that the Committee members have the relevant financial experience and the
expertise to resource and fulfil its responsibilities effectively, including
those relating to risk and controls.
Meetings
The Committee meets two times a year, including the review of the interim and
full year results. Other Directors and representatives from the external
auditors attend by invitation.
Duties
The Committee carries out the duties below for the Company, as appropriate:
§ Monitors the integrity of the financial statements of the Company,
including annual and half-yearly reports, interim management statements, and
any other formal announcement relating to financial performance, reviewing
significant financial reporting issues and judgements which they contain.
§ Reviews and challenges the consistency of the information presented
within the financial statements, compliance with stock exchange or other legal
requirements, accounting policies and the methods used to account for
significant or unusual transactions.
§ Keeps under review the effectiveness of the Company's internal controls
and risk management systems.
§ KPMG Audit LLC was appointed as auditor in 2011 and the ARCC will oversee
the relationship with them including meetings when considered appropriate to
discuss their remit and review the findings and any issues with the annual
audit. It will also review their terms of appointment and plans to meet them
once a year independent of management and will consider and make
recommendations to the Board, to be put to the Company for approval at the
Annual General Meeting, in relation to the appointment, re-appointment and
removal of the Company's external auditor. There are no contractual
restrictions in place in respect of the auditor choice.
§ The Committee is governed by a Terms of Reference and a copy of this is
available on the Company's website.
2023 Annual Report
During the year, ARCC confirms that it has received sufficient, reliable and
timely information from management and the external auditors to enable it to
fulfil its responsibilities.
The Committee has satisfied itself that there are no relationships between the
auditor and the Company which could adversely affect the auditor's
independence and objectivity.
All internal control and risk issues that have been brought to the attention
of ARCC by the external auditors have been considered and the Committee
confirms that it is satisfied that management has addressed the issues or has
plans to do so.
The Company has a number of policies and procedures in place as part of its
internal controls and these are subject to continuous review and as a minimum
are reviewed by ARCC on an annual basis.
ARCC has reviewed and discussed together with management and the external
auditor the Company's financial statements for the year ended 30 June 2023 and
reports from the external auditor on the planning for and outcome of their
reviews and audit. The key accounting issues and judgements considered
relating to the Company's financial statements and disclosures were as
follows:
§ Valuation of unquoted investments £141,595,967;
§ Going concern - ARCC reviewed the going concern position of the Company,
taking into account the 12-month cash flow forecasts. ARCC is satisfied that
preparing the financial statements on a going concern basis is appropriate.
Richard Reed
Chairperson ARCC
21 December 2023
Report of the Remuneration Committee
As an Isle of Man registered company there is no requirement to produce a
Directors' Remuneration Report. However, the Board follows best practice and
therefore has prepared such a report.
The Directors have agreed to comply with the provisions of the Quoted
Companies Alliance ("QCA") Corporate Governance Code for Small and Mid-Size
Quoted Companies (2018) to the extent which is appropriate to its nature and
scale of operations.
This report illustrates how the Company complies with those principles in
relation to directors' remuneration.
The Level and Components of Non-Executive Directors Remuneration
The Remuneration Policy reflects the Company's business strategy and
objectives as well as sustained and long-term value creation for shareholders.
In addition, the policy aims to be fair and provide equality of opportunity,
ensuring that:
§ the Company is able to attract, develop and retain high-performing and
motivated people in the competitive local and wider markets;
§ The Company offers a competitive remuneration package to encourage
enhanced performance and rewards individual contributions to the success of
the Company, in a fair and responsible manner;
§ it reflects the Company's culture and values; and
§ there is full transparency of the Remuneration Policy.
In line with the Board's approach, which reflects that adopted within other
comparable organisations, the Remuneration Policy provides for the reward of
the Non-Executive Directors through fees and other benefits.
Non-Executive Directors Emoluments
The remuneration for the Non-Executive Directors reflects their
responsibilities. It comprises fees and may include eligibility to participate
in an annual bonus scheme, private healthcare and share option incentives,
when any of these are considered appropriate.
Annual bonus scheme payments are not pensionable and are not contracted.
Non-executive Directors' Remuneration
Non-executive Directors do not receive any benefits other than their fees and
travelling expenses for which they are reimbursed. The level of fees payable
to Non-executive Directors is assessed using benchmarks from a group of
comparable organisations.
Executive Directors Remuneration
Executive Directors do not receive any benefits other than their fees and
travelling expenses for which they are reimbursed. The level of fees payable
to Executive Directors is assessed using benchmarks from a group of comparable
organisations.
The Committee believes that share ownership by executives strengthens the link
between their personal interests and those of shareholders. Options will be
granted to executives periodically at the discretion of the Remuneration
Committee. The grant of share options is not subject to fixed performance
criteria. This is deemed to be appropriate as it allows the Committee to
consider the performance of the executives and the contribution of the
individual executives and, as with annual bonus payments, illustrates the
relative importance placed on performance-related remuneration.
Except when required by statute, the Company does not intend to contribute to
the personal pension plans of Directors in the forthcoming year.
Executive Directors' Contractual Terms
The service contract of the Executive Directors provides for a notice period
of six months.
The Procedure for Determining Remuneration
The Remuneration Committee, comprising two Non-executive Directors and one
Executive Director, is responsible for setting the remuneration of the
Executive Directors and is chaired by Jim Mellon. Committee members do not
take part in discussions concerning their own remuneration. The basic
Non-executive Director fee is set by the Chairperson. The Chairperson of the
Committee reports at the Board meeting following a Committee meeting.
It is the view of the Committee that Directors' remuneration awarded across
the Company for the year has been in accordance with the Company's stated
Remuneration Policy and, on behalf of the Committee I recommend that you
endorse this report. An analysis of Directors' emoluments is as follows:
2023 2022
£ £
Emoluments - salaries, bonuses, and taxable benefits - -
- fees 117,709 85,000
117,709 85,000
Directors' Emoluments
Bonus Termination 2023 2022
Fees £ payments Benefits Total Total
£ £ £ £ £
Executive - salary
Denham Eke ** - - - - - -
Jim Mellon* 30,000 - - - 30,000 15,000
Non-executive - fees
Richard Reed 40,000 - - - 40,000 40,000
David Giampaolo 30,000 - - - 30,000 30,000
Marisa Drew 17,709 - - - 17,709 -
Aggregate emoluments 117,709 - - - 117,709 85,000
* In addition to director fees, further emoluments are subject to an agreement
with Shellbay Investments Limited ("Shellbay"), whereby Shellbay shall be
entitled to an annual fee equal to the value of 15% of any increase between
the Company's net asset value ("NAV") on a per issued share basis at the start
of a reporting period and 30 June each year during the term of the New
Shellbay Agreement (please see Note 2 to the Accounts).
** Denham Eke was appointed as a Director on 30 May 2012 and currently
receives no remuneration for providing his services (refer note 10).
Approval
The report was approved by the Board of directors and signed on behalf of the
Board.
Jim Mellon
Chairperson of Remuneration Committee
21 December 2023
Statement of Directors' Responsibilities in Respect of the Directors' Report
and the Financial Statements
The Directors are responsible for preparing the Directors' Report and the
financial statements in accordance with applicable law and regulations.
Company law requires the Directors to prepare financial statements for each
financial year. Under that law they have elected to prepare the financial
statements in accordance with International Financial Reporting Standards as
applicable to an Isle of Man company and applicable law.
Under company law the Directors must not approve the financial statements
unless they are satisfied that they give a true and fair view of the state of
affairs of the Company and of its profit or loss for that period. In preparing
the financial statements, the Directors are required to:
· select suitable accounting policies and then apply them
consistently;
· make judgements and estimates that are reasonable, relevant and
reliable;
· state whether they have been prepared in accordance with IFRSs;
· assess the Company's ability to continue as a going concern,
disclosing, as applicable, matters related to going concern; and
· use the going concern basis of accounting unless they either
intend to liquidate the Company or to cease operations or have no realistic
alternative but to do so.
The Directors are responsible for keeping adequate accounting records that are
sufficient to show and explain the Company's transactions and disclose with
reasonable accuracy at any time the financial position of the Company and
enable them to ensure that its financial statements comply with the Isle of
Man Companies Act 2006. They are responsible for such internal control as they
determine is necessary to enable the preparation of financial statements that
are free from material misstatement, whether due to fraud or error, and have
general responsibility for taking such steps as are reasonably open to them to
safeguard the assets of the Company and to prevent and detect fraud and other
irregularities.
The Directors are responsible for the maintenance and integrity of the
corporate and financial information included on the Company's website.
Legislation in the Isle of Man governing the preparation and dissemination of
financial statements may differ from legislation in other jurisdictions.
Our opinion is unmodified
We have audited the financial statements of Agronomics Limited (the
"Company"), which comprise the statement of financial position as at 30 June
2023, the statements of profit or loss and other comprehensive income,
changes in equity and cash flows for the year then ended, and notes,
comprising significant accounting policies and other explanatory information.
In our opinion, the accompanying financial statements:
· give a true and fair view of the state of the Company's affairs
as at 30 June 2023 and of the Company's profit for the year then ended;
· have been properly prepared in accordance with International
Financial Reporting Standards; and
· have been properly prepared in accordance with the requirements
of the Companies Act 2006.
Basis for opinion
We conducted our audit in accordance with International Standards on Auditing
(UK) ("ISAs (UK)") and applicable law. Our responsibilities are described
below. We have fulfilled our ethical responsibilities under, and are
independent of the Company in accordance with, UK ethical requirements
including the FRC Ethical Standard as applied to listed entities. We believe
that the audit evidence we have obtained is a sufficient and appropriate basis
for our opinion.
Key audit matters: our assessment of the risks of material misstatement
Key audit matters are those matters that, in our professional judgment, were
of most significance in the audit of the financial statements and include the
most significant assessed risks of material misstatement (whether or not due
to fraud) identified by us, including those which had the greatest effect on:
the overall audit strategy; the allocation of resources in the audit; and
directing the efforts of the engagement team. These matters were addressed in
the context of our audit of the financial statements as a whole, and in
forming our opinion thereon, and we do not provide a separate opinion on these
matters. In arriving at our audit opinion above, the key audit matter was
as follows (unchanged from 2022):
The risk Our response
Valuation of unquoted investments (including investment in subsidiary and Subjective Valuation: Our audit procedures included:
other unquoted investments held)
The Company's investment in subsidiary is stated at fair value of Internal Controls: Assessing the design and implementation of the investment
2023: £141,773,297 (2022 £94,813,088) £134,178,896 (2022: £87,766,747). The underlying portfolio of investments valuation processes and controls.
held by the subsidiary comprises the entirety of its net assets. The Company
Refer to Page 12 for Audit, Risk and Compliance Committee Report, note 1(b) also holds unquoted investments directly amounting to £7,417,071 (2022: Test of Detail: Auditing the accounts of the subsidiary as part of the audit
(use of estimates and judgement), 1(d) (accounting policy for financial £6,795,650). of the Company, including assessing the accounting policies adopted by the
instruments) and note 8 (fair value of financial instruments) disclosures
subsidiary to ensure these are consistent with the Company's accounting
83% (2022: 60%) of the Company's total assets (by value) are held in policies. In particular, ensuring that the portfolio of investments held by
investments where no quoted market price is available. Unquoted investments the subsidiary is stated at fair value and ensuring net asset value of the
held directly by the Company, and indirectly through the underlying portfolio subsidiary represents fair value.
in its subsidiary, are measured at fair value, which is established in
accordance with the International Private Equity and Venture Capital Valuation Use of KPMG Specialists: Involving our own valuation specialists to challenge
Guidelines by using measurements of value such as comparison with prices of management assumptions used to support the fair value prices.
recent orderly transactions, where available, requires the use of significant
judgments and subjective assumptions.
The risk Our response
Subjective Valuation: Challenging managements' assumptions and inputs: Challenging the directors on
key judgments affecting investee company valuations, such as the achievement
The preparation of the fair value estimate for the unquoted investments and of key milestones or potential dilution impacts of recent transactions. Our
related disclosures is a significant area of our audit given that it work included consideration of events which occurred subsequent to the year
represents a significant portion of the Company's total assets and involves end up until the date of this report.
the use of significant judgments and subjective assumptions.
Assessing observable inputs: Where a recent transaction has been used as a
The effect of these matters is that as part of our risk assessment, we basis to value a holding, we obtained an understanding of the circumstances
determined that the valuation of unquoted investments has a high degree of surrounding the transaction such as whether it was considered to be on an
estimation uncertainty, with a potential range of reasonable outcomes greater arms-length basis and suitable as an input into a valuation.
than our materiality for the financial statements as a whole and possibly many
times that amount. Methodology choice: In the context of observed industry best practice and the
provisions of the International Private Equity and Venture Capital Valuation
Guidelines, we challenged the appropriateness of the valuation basis selected.
Assessing disclosures: Consideration of the appropriateness, in accordance
with relevant accounting standards, of the disclosures in respect of unquoted
investments and the significant inherent uncertainty associated with valuing
such investments.
Our application of materiality and an overview of the scope of our audit
Materiality for the financial statements as a whole was set at £1,260,000
(2022: £1,200,000), determined with reference to a benchmark of total
assets of £164 million, of which it represents approximately 0.8% (2022:
0.8%).
In line with our audit methodology, our procedures on individual account
balances and disclosures were performed to a lower threshold, performance
materiality, so as to reduce to an acceptable level the risk that individually
immaterial misstatements in individual account balances add up to a material
amount across the financial statements as a whole. Performance materiality for
the Company was set at 65% (2022: 65%) of materiality for the financial
statements as a whole, which equates to £819,000 (2022: £780,000). We
applied this percentage in our determination of performance materiality
because we did not identify any factors indicating an elevated level of risk.
We reported to the Audit Committee any corrected or uncorrected identified
misstatements exceeding £63,000 (2022: £60,000), in addition to other
identified misstatements that warranted reporting on qualitative grounds.
Our audit of the Company was undertaken to the materiality level specified
above, which has informed our identification of significant risks of material
misstatement and the associated audit procedures performed in those areas as
detailed above.
Going concern
The directors have prepared the financial statements on the going concern
basis as they do not intend to liquidate the Company or to cease its
operations, and as they have concluded that the Company's financial position
means that this is realistic. They have also concluded that there are no
material uncertainties that could have cast significant doubt over its ability
to continue as a going concern for at least a year from the date of approval
of the financial statements (the "going concern period").
In our evaluation of the directors' conclusions, we considered the inherent
risks to the Company's business model and analysed how those risks might
affect the Company's financial resources or ability to continue operations
over the going concern period. The risks that we considered most likely to
affect the Company's financial resources or ability to continue operations
over this period were:
· Availability of capital to meet operating costs and other financial
commitments; and
· The recoverability of financial assets subject to credit risk;
We considered whether these risks could plausibly affect the liquidity in the
going concern period by comparing severe, but plausible downside scenarios
that could arise from these risks individually and collectively against the
level of available financial resources indicated by the Company's financial
forecasts.
We considered whether the going concern disclosure in note 1(b) to the
financial statements gives a full and accurate description of the directors'
assessment of going concern.
Our conclusions based on this work:
· we consider that the directors' use of the going concern basis of
accounting in the preparation of the financial statements is appropriate;
· we have not identified, and concur with the directors' assessment
that there is not, a material uncertainty related to events or conditions
that, individually or collectively, may cast significant doubt on the the
Company's ability to continue as a going concern for the going concern period;
and
· we found the going concern disclosure in the notes to the financial
statements to be acceptable.
However, as we cannot predict all future events or conditions and as
subsequent events may result in outcomes that are inconsistent with judgements
that were reasonable at the time they were made, the above conclusions are not
a guarantee that the Company will continue in operation.
Fraud and breaches of laws and regulations - ability to detect
Identifying and responding to risks of material misstatement due to fraud
To identify risks of material misstatement due to fraud ("fraud risks") we
assessed events or conditions that could indicate an incentive or pressure to
commit fraud or provide an opportunity to commit fraud. Our risk assessment
procedures included:
· enquiring of management as to the Company's policies and procedures
to prevent and detect fraud as well as enquiring whether management have
knowledge of any actual, suspected or alleged fraud;
· reading minutes of meetings of those charged with governance; and
· using analytical procedures to identify any unusual or unexpected
relationships.
As required by auditing standards, and taking into account possible incentives
or pressures to misstate performance and our overall knowledge of the control
environment, we perform procedures to address the risk of management override
of controls, in particular the risk that management may be in a position to
make inappropriate accounting entries, and the risk of bias in accounting
estimates such as valuation of unquoted investments. On this audit we do not
believe there is a fraud risk related to revenue recognition because the
Company's revenue streams are simple in nature with respect to accounting
policy choice, and are easily verifiable to external data sources or
agreements with little or no requirement for estimation from management. We
did not identify any additional fraud risks.
We performed procedures including:
· identifying journal entries and other adjustments to test based on
risk criteria and comparing any identified entries to supporting
documentation;
· incorporating an element of unpredictability in our audit procedures;
and
· those set out in the valuation of unquoted investments key audit
matter.
Identifying and responding to risks of material misstatement due to non-compliance with laws and regulations
We identified areas of laws and regulations that could reasonably be expected
to have a material effect on the financial statements from our sector
experience and through discussion with management (as required by auditing
standards), and from inspection of the Company's regulatory and legal
correspondence, if any, and discussed with management the policies and
procedures regarding compliance with laws and regulations. As the Company is
regulated, our assessment of risks involved gaining an understanding of the
control environment including the entity's procedures for complying with
regulatory requirements.
Identifying and responding to risks of material misstatement due to non-compliance with laws and regulations (continued)
The Company is subject to laws and regulations that directly affect the
financial statements including financial reporting legislation and taxation
legislation and we assessed the extent of compliance with these laws and
regulations as part of our procedures on the related financial statement
items.
The Company is subject to other laws and regulations where the consequences of
non-compliance could have a material effect on amounts or disclosures in the
financial statements, for instance through the imposition of fines or
litigation or impacts on the Company's ability to operate. We identified
financial services regulation as being the area most likely to have such an
effect, recognising the regulated nature of the Company's activities and its
legal form. Auditing standards limit the required audit procedures to identify
non-compliance with these laws and regulations to enquiry of management and
inspection of regulatory and legal correspondence, if any. Therefore, if a
breach of operational regulations is not disclosed to us or evident from
relevant correspondence, an audit will not detect that breach.
Context of the ability of the audit to detect fraud or breaches of law or regulation
Owing to the inherent limitations of an audit, there is an unavoidable risk
that we may not have detected some material misstatements in the financial
statements, even though we have properly planned and performed our audit in
accordance with auditing standards. For example, the further removed
non-compliance with laws and regulations is from the events and transactions
reflected in the financial statements, the less likely the inherently limited
procedures required by auditing standards would identify it.
In addition, as with any audit, there remains a higher risk of non-detection
of fraud, as this may involve collusion, forgery, intentional omissions,
misrepresentations, or the override of internal controls. Our audit procedures
are designed to detect material misstatement. We are not responsible for
preventing non-compliance or fraud and cannot be expected to detect
non-compliance with all laws and regulations.
Other information
The directors are responsible for the other information. The other
information comprises the information included in the annual report but does
not include the financial statements and our auditor's report thereon. Our
opinion on the financial statements does not cover the other information and
we do not express an audit opinion or any form of assurance conclusion
thereon.
In connection with our audit of the financial statements, our responsibility
is to read the other information and, in doing so, consider whether the other
information is materially inconsistent with the financial statements or our
knowledge obtained in the audit, or otherwise appears to be materially
misstated. If, based on the work we have performed, we conclude that there is
a material misstatement of this other information, we are required to report
that fact. We have nothing to report in this regard.
Respective responsibilities
Directors' responsibilities
As explained more fully in their statement set out on 17, the directors are
responsible for: the preparation of the financial statements including being
satisfied that they give a true and fair view; such internal control as they
determine is necessary to enable the preparation of financial statements that
are free from material misstatement, whether due to fraud or error; assessing
the Company's ability to continue as a going concern, disclosing, as
applicable, matters related to going concern; and using the going concern
basis of accounting unless they either intend to liquidate the Company or to
cease operations, or have no realistic alternative but to do so.
Auditor's responsibilities
Our objectives are to obtain reasonable assurance about whether the financial
statements as a whole are free from material misstatement, whether due to
fraud or error, and to issue our opinion in an auditor's report. Reasonable
assurance is a high level of assurance, but does not guarantee that an audit
conducted in accordance with ISAs (UK) will always detect a material
misstatement when it exists. Misstatements can arise from fraud or error and
are considered material if, individually or in aggregate, they could
reasonably be expected to influence the economic decisions of users taken on
the basis of the financial statements.
A fuller description of our responsibilities is provided on the FRC's website
at www.frc.org.uk/auditorsresponsibilities
(http://www.frc.org.uk/auditorsresponsibilities) .
The purpose of this report and restrictions on its use by persons other than the Company's members, as a body
This report is made solely to the Company's members, as a body, in accordance
with section 80(C) of the Companies Act 2006. Our audit work has been
undertaken so that we might state to the Company's members those matters we
are required to state to them in an auditor's report and for no other purpose.
To the fullest extent permitted by law, we do not accept or assume
responsibility to anyone other than the Company and the Company's members, as
a body, for our audit work, for this report, or for the opinions we have
formed.
KPMG Audit LLC
Chartered Accountants
Heritage Court
41 Athol Street
Douglas
Isle of Man IM1 1LA
21 December 2023
Statement of comprehensive income
for the year ended 30 June 2023
2023 2022
Note £ £
Income
Net income from financial instruments at fair value through profit and loss 3 29,703,324 6,423,869
──────── ────────
29,703,324 6,423,869
Operating expenses
Directors' fees 2 (117,709) (85,000)
Other operating costs 4 (1,648,101) (1,753,868)
Foreign exchange (losses)/gains (3,364,673) 6,513,031
──────── ────────
Profit from operating activities 5 24,572,841 11,098,032
Other costs
Consulting fee 2 (3,372,672) (4,562,548)
Recoverable / (Irrecoverable) VAT - 1,478,872
──────── ────────
Profit after consulting fee 21,200,169 8,014,356
Interest received 1,173,507 344,023
──────── ────────
Profit before taxation 22,373,676 8,358,379
Taxation 1(h) - -
──────── ────────
Profit for the year 22,373,676 8,358,379
Other comprehensive income - -
──────── ────────
Total comprehensive profit for the year 22,373,676 8,358,379
════════ ════════
Basic profit per share (pence) 11 2.27 0.95
Diluted profit per share (pence) 11 2.20 0.91
The Directors consider that the Company's activities are continuing.
The notes on pages 25 to 39 form an integral part of these financial
statements.
Statement of financial position
as at 30 June 2023
2023 2022
Note £ £
Assets
Financial assets at fair value through profit or loss 7,8 141,773,297 94,813,088
Bank deposits 10,000,000 20,024,175
Trade and other receivables 335,810 102,659
Cash and cash equivalents 18,093,984 31,458,326
──────── ────────
Total assets 170,203,091 146,398,248
════════ ════════
Equity and liabilities
Capital and reserves
Share capital 6 992 968
Share premium 6 134,481,365 129,855,667
Share reserve 6 1,686,336 4,341,639
Accumulated earnings 32,088,305 9,714,629
──────── ────────
168,256,998 143,912,903
Liabilities
Trade and other payables 9 1,946,093 2,485,345
──────── ────────
Total liabilities 1,946,093 2,485,345
──────── ────────
Total equity and liabilities 170,203,091 146,398,248
════════ ════════
The notes on pages 25 to 39 form an integral part of these financial
statements.
These financial statements were approved by the Board of Directors on 21
December 2023 and were signed on their behalf by:
Denham Eke
Finance Director
Statement of changes in equity
for the year ended 30 June 2023
Note Share Share Share Accumulated
capital premium reserve earnings Total
£ £ £ £ £
Balance at 30 June 2021 6 799 91,278,407 7,394,360 1,356,250 100,029,816
Total comprehensive profit for the year
Profit for the year - - - 8,358,379 8,358,379
Transactions with owners of the company
Shares issued during the year 6 169 39,439,051 (7,394,360) - 32,044,860
Capitalised share issue costs 6 - (861,791) - - (861,791)
Recognition of share reserve 6 - - 4,341,639 - 4,341,639
──────── ──────── ──────── ──────── ────────
Balance at 30 June 2022 6 968 129,855,667 4,341,639 9,714,629 143,912,903
════════ ════════ ════════ ════════ ════════
Note Share Share Share Accumulated
capital premium reserve earnings Total
£ £ £ £ £
Balance at 30 June 2022 6 968 129,855,667 4,341,639 9,714,629 143,912,903
Total comprehensive profit for the year
Profit for the year - - - 22,373,676 22,373,676
Transactions with owners of the company
Shares issued during the year 6 24 4,625,698 (4,341,639) - 284,083
Recognition of share reserve 6 - - 1,686,336 - 1,686,336
──────── ──────── ──────── ──────── ────────
Balance at 30 June 2023 6 992 134,481,365 1,686,336 32,088,305 168,256,998
════════ ════════ ════════ ════════ ════════
The notes on pages 25 to 39 form an integral part of these financial
statements.
Statement of cash flows
for the year ended 30 June 2023
2023 2022
Note £ £
Cash flows from operating activities
Operating profit for the year 22,373,676 8,358,379
Purchase of investments 8 (19,542,137) (42,032,410)
Proceeds from sale of investments 8 - 696,456
Interest income (1,173,507) (341,329)
Realised and unrealised gains on investments 3 (29,703,324) (12,362,604)
Unrealised foreign exchange losses on investments 8 2,729,121 -
Consulting fee to be settled in shares 2 1,686,336 2,281,274
─────── ───────
Operating outflows before changes in working capital (23,629,835) (43,400,234)
Change in trade and other receivables (233,152) 318,395
Change in trade and other payables 9 (539,252) 873,841
─────── ───────
Net cash used in operating activities (24,402,239) (42,207,998)
─────── ───────
Cash flows from financing activities
Proceeds from issue of shares 284,082 32,057,951
Share issue commissions paid - (861,791)
Cash interest received 729,639 57,842
─────── ───────
Net cash from financing activities 1,013,721 31,254,002
─────── ───────
Cash flows from investing activities
Bank deposits not considered cash and cash equivalents (net movement) 10,024,176 (20,024,175)
─────── ───────
Net cash from investing activities 10,024,176 (20,024,175)
─────── ───────
Decrease in cash and cash equivalents (13,364,342) (30,978,171)
Cash and cash equivalents at beginning of year 31,458,326 62,436,497
─────── ───────
Cash and cash equivalents at the end of year 18,093,984 31,458,326
═══════ ═══════
The notes on pages 25 to 39 form an integral part of these financial
statements.
1 Accounting policies
Agronomics Limited is a Company domiciled in the Isle of Man. The Company's
strategy is to create value for Shareholders through investing in companies
that operate in the nascent industry of modern foods, which are
environmentally friendly alternatives to the traditional production of meat
and plant-based sources.
The principal accounting policies are set out below.
a) Statement of compliance
The financial statements have been prepared in accordance with International
Financial Reporting Standards ("IFRS"). There has been no material impact on
the financial statements of new standards/interpretations that have come into
effect during the current year.
b) Basis of preparation
The financial statements are prepared under the historical cost convention
except where assets and liabilities are required to be stated at their fair
value.
Use of estimates and judgment
The preparation of financial statements in conformity with IFRS requires
management to make judgements, estimates and assumptions that affect the
application of policies and reported amounts of assets and liabilities, income
and expenses. The estimates and associated assumptions are based on historical
experience and various other factors that are believed to be reasonable under
the circumstances, the results of which form the basis of making the
judgements about carrying values of assets and liabilities that are not
readily apparent from other sources. Actual results may differ from these
estimates.
The estimates and underlying assumptions
are reviewed on an on-going basis. Revisions to accounting estimates are
recognised in the period in which the estimate is revised if the revision only
affects that period or in the period of the revision and future periods if the
revision affects both current and future periods.
Judgements made by the Directors in the application of IFRS, that have a
significant impact on the financial statements and estimates with a
significant risk of material adjustment in the next financial year relate to
valuation of financial assets at fair value through profit or loss. The
determination of fair values for financial assets for which there is no
observable market price requires judgment as to the selection of valuation
techniques as described in accounting policy 1(d). For financial instruments
that trade infrequently and have little price transparency, fair value is less
objective, and requires varying degrees of judgement and estimation depending
on liquidity, concentration, uncertainty of market factors, pricing
assumptions and other risks affecting the specific instrument. The portfolio
companies are all in the start-up/development stage and in the biotechnology
and biopharmaceutical sector. By their nature, such companies are difficult to
value, as they have little or no track record regarding sales and margins and
may be subject to continued funding being available in order to continue in
operation. The eventual outcome may differ materially from the value estimate.
See also note 8 in respect of the valuation of financial instruments.
Going concern
The financial statements have been prepared on a going concern basis, taking
into consideration the level of cash and liquid investments held by the
Company. The Directors have a reasonable expectation that the Company will
have adequate resources for its continuing existence and projected activities
for the foreseeable future, and for these reasons, continue to adopt the going
concern basis in preparing the financial statements for the year ended 30 June
2023.
Functional and presentation currency
These financial statements are presented in Pound Sterling (£) which is the
Company's functional currency and rounded to the nearest pound.
c) Net income from financial
instruments at fair value through profit and loss
Any realised and unrealised gains and losses on investments are presented
within 'net income from financial instruments at fair value through profit or
loss'.
Interest income earned during the period,
is accrued on a time apportionment basis, by reference to the principal
outstanding and the effective rate applicable.
Dividend income is recognised when a
security held goes ex-dividend. Dividends are shown as net cash received,
after the deduction of withholding taxes.
d) Financial instruments
Recognition and initial
measurement
The Company recognises financial assets and financial liabilities at fair
value through profit and loss ("FVTPL") on the trade date, which is the date
on which the Company becomes party to the contractual provisions of the
instrument. A financial asset or financial liability is measured initially at
fair value plus, for an item not at FVTPL, transaction costs that are directly
attributable to its acquisition or issue.
Classification
On initial recognition, the Company classifies financial assets as measured at
amortised cost or FVTPL.
A financial asset is measured at amortised cost if it meets both of the
following conditions and is not designated as at FVTPL:
· it is held within a business model whose objective is to hold
assets to collect contractual cash flows; and
· its contractual terms give rise on specified dates to cash flows
that are solely payment of principal and interest ("SPPI").
All other financial assets of the Company are measured at FVTPL.
Business model assessment
In making an assessment of the objective of the business model in which a
financial asset is held, the Company considers all of the relevant information
about how the business is managed, including:
· the documented investment strategy and the execution of this
strategy in practice. This includes whether the investment strategy focuses on
earning contractual interest income, maintaining a particular interest rate
profile, matching the duration of the financial assets to the duration of any
related liabilities or expected cash outflows or realising cash flows through
the sale of the assets;
· how the performance of the portfolio is evaluated and reported to
the Company's management;
· the risks that affect the performance of the business model (and
the financial assets held within that business model) and how those risks are
managed;
· how the investment manager is compensated: e.g. whether
compensation is based on the fair value of the assets managed or the
contractual cash flows collected; and
· the frequency, volume and timing of sales of financial assets in
prior periods, the reasons for such sales and expectations about future sales
activity.
Transfers of financial assets to third parties in transactions that do not
qualify for derecognition are not considered sales for this purpose,
consistent with the company's continuing recognition of the assets.
The Company has determined that it has two business models.
Held-to-collect business model: this includes cash and cash equivalents and
bank deposits. These financial assets are held to collect contractual cash
flow.
Other business model: this includes debt securities, equity investments both
quoted and unquoted. These financial assets are managed and their performance
is evaluated, on a fair value basis.
Fair value measurement
principles
The fair value
of investment holdings of listed investments is based on their quoted market
prices at the reporting date on a recognised exchange or in the case of
non-exchange traded instruments, sourced from a reputable counterparty,
without any deduction for estimated future selling costs. Financial assets are
priced at their closing bid prices, while financial liabilities are priced at
their closing offer prices.
Company assets may, at any time include securities and other financial
instruments or obligations that are thinly traded or for which no market
exists and/or which are restricted as to their transferability under
securities laws.
d) Financial instruments (continued)
Fair value measurement principles (continued)
If a quoted market price is not available
on a recognised stock exchange, or a market is not sufficiently active for the
market price to be considered reliable, or if a price is not available from a
reputable counterparty, fair value of the financial instruments may be
estimated by the Directors using valuation techniques, including use of recent
arm's length market transactions, reference to the current fair value of
another instrument that is substantially the same, discounted cash flow
techniques, option pricing models or any other valuation technique that
provides a reliable estimate of prices obtained in actual market transactions.
The Company recognizes transfers between levels of the fair value hierarchy as
at the end of the reporting period during which the change occurred.
Reclassifications
Financial assets are not reclassified subsequent to their initial recognition
unless the Company were to change its business model for managing financial
assets, in which case all affected financial assets would be reclassified on
the first day of the first reporting period following the change in the
business model.
Impairment
The Company recognises loss allowances for Expected Credit Losses ("ECLs") on
financial assets measured at amortised cost.
The Company measures loss allowances at an amount equal to lifetime ECLs,
except for the following, which are measured at 12-month ECLs:
· financial assets that are determined to have low credit risk at
the reporting date; and
· other financial assets for which credit risk (i.e. the risk of
default occurring over the expected life of the asset) has not increased
significantly since initial recognition.
Derecognition
The Company derecognises a financial asset when the contractual rights to the
cash flows from the asset expire, or it transfers the rights to receive the
contractual cash flows in a transaction in which substantially all of the
risks and rewards of ownership of the financial asset are transferred or in
which the Company neither transfers nor retains substantially all of the risks
and rewards of ownership and does not retain control of the financial asset.
On derecognition of a financial asset, the difference between the carrying
amount of the asset (or the carrying amount allocated to the portion of the
asset that is derecognised) and the consideration received (including any new
asset obtained less any new liability assumed) is recognised in profit or
loss. Any interest in such transferred financial assets that is created or
retained by the Company is recognised as a separate asset or liability.
Cash and cash equivalents
Cash and cash equivalents comprise cash
balances and call deposits with maturities of three months or less from the
acquisition date that are subject to an insignificant risk of changes in fair
value.
Trade and other receivables
Trade and other receivables originated by
the Company are initially recognised at fair value and subsequently stated at
amortised cost less impairment losses.
Trade and other payables
Trade and other payables are initially
recognised at fair value less directly attributable transaction costs.
Subsequently they are measured at amortised cost using the effective interest
method.
e) Share capital and share premium
Ordinary shares are classified as equity.
The ordinary shares of the Company have a par value of £0.000001 each. Excess
proceeds received for the issue of shares has been credited to share premium.
Incremental costs directly attributable to the issue of ordinary shares are
recognised as a deduction from equity, net of any tax effects.
f) Foreign currencies
Transactions in foreign currencies are translated into the functional currency
at the rate ruling at the date of the transaction. Monetary assets and
liabilities denominated in foreign currencies are translated into the
functional currency at the exchange rate at the reporting date. Non-monetary
assets and liabilities that are measured at fair value in a foreign exchange
currency are translated into the functional currency at the exchange rate when
the fair
f) Foreign currencies (continued)
value was determined. Non-monetary items that are measured based on historical
cost in a foreign currency are translated at the exchange rate at the date of
the transaction.
Foreign currency differences are generally recognised in profit or loss and
presented as foreign exchange gains / (losses).
g) New standards and interpretations
not yet adopted
A number of new standards, amendments to standards and interpretations are not
yet effective for the year, and have not been applied in preparing these
historical financial statements:
New/revised International Accounting Standards / International Financial EU Effective date
Reporting Standards ("IAS/IFRS")
(accounting periods commencing on or after)
Classification of liabilities as current or non-current (Amendments to IAS 1) 1 January 2024
IFRS 17 Insurance Contracts 1 January 2023
Amendments to IFRS 17 1 January 2023
Disclosure of Accounting Policies (Amendments to IAS1 and IFRS Practice 1 January 2023
Statement 2)
Definition of Accounting Estimate (Amendments to IAS 8) 1 January 2023
Deferred Tax related Asset and Liabilities Arising from a Single Transaction - 1 January 2023
Amendments to IAS 12 Income Taxes
Sale or Contribution of Assets between an Investor and its Associate or Joint 1 January 2023
Ventures (Amendments to FRS 10 and IAS 28)
The Directors do not expect the adoption of the standards and interpretations
to have a material impact on the financial statements in the period of initial
application. There are no other standards, amendments or interpretations to
existing standards that are not yet effective, that would have a material
impact on the Company's reported results.
There has been no material impact on the
Company's financial statements of new standards or interpretations that have
come into effect during the current reporting period.
h) Taxation
The Company is subject to income tax at a rate of 0% in the Isle of Man, and
accordingly, no tax has been provided for in these financial statements.
The Company may be subject to withholding
taxes in relation to income from investments, or investment realisation
proceeds or gains, and such amounts will be accounted for as incurred.
i) Segmental reporting
The Directors are of the opinion that the Company is engaged in a single
segment of business,
being investing in companies that operate in the nascent industry of modern
foods, which are environmentally friendly alternatives to the traditional
production of meat and plant-based sources. Information presented to the Board
of Directors for the purpose of decision making is based on this single
segment and in accordance with IFRS.
j) Investment entity
The Company is an investment entity and measures investments in its
subsidiaries at FVTPL. In determining whether the Company meets the definition
of an investment entity, management considered the Company structure as a
whole. In particular, when assessing the existence of investment exit
strategies and whether the Company or its subsidiary has more than one
investment, management took into consideration the fact that the subsidiary
was formed in order to hold investments on behalf of the Company. Management
concluded that the Company and the subsidiary each meet the definition of an
investment entity. Consequently, management concluded that the Company should
not consolidate the subsidiary.
k) Comparative information
Where appropriate, figures in the comparative financial year have been
reclassified in order to present them in a manner consistent with the current
financial period.
2 Directors' and consulting fees
The fees of Directors who served during the year ended 30 June 2023 were as
follows:
2023 2022
£ £
Richard Reed 40,000 40,000
David Giampaolo 30,000 30,000
Jim Mellon 30,000 15,000
Marisa Drew 17,709 -
─────── ───────
117,709 85,000
═══════ ═══════
Denham Eke was appointed as a Director on 30 May 2012 and currently receives
no remuneration for providing his services (refer note 10).
On 6 May 2011, Shellbay Investments Limited ("Shellbay") entered into a Letter
of Appointment with the Company to provide certain services to Agronomics. In
May 2021, following shareholder feedback and in consultation with the
Company's advisers, the terms of this agreement were altered, on the basis
that from May 2021 new arrangements would be put in place to (i) ensure the
terms of Shellbay's appointment were consistent with market standard terms for
commensurate services; (ii) provide greater transparency and corporate
governance regarding the role of Shellbay; and (iii) establish a remuneration
structure fully aligned with shareholders, and acceptable to existing and
future investors. The effective date for the updated agreement is 01 July
2020.
Under the updated terms, Shellbay will provide certain services to Agronomics,
including:
- Reviewing prospective asset purchases;
- Procuring and coordinating due diligence in relation to any
target approved by the Company;
- Providing appropriate information to the Board in relation to
any proposed acquisition or disposal opportunity;
- Providing transaction support services as requested by the
Company;
- Assisting in operating, developing and commercialising any
intellectual property and/or assets of the Company (including by way of joint
venture, licensing agreement or other partnership);
- Developing new markets and/or territories for assets and/or
intellectual property owned by the Company (including by way of manufacturing,
distribution and/or branding partnerships);
- Supplying the Board with regular reports on the progress of
companies and intellectual property where the Company has an interest
(including any financings);
- Assisting with recruitment of management teams and operational
supply chain partners for relevant products and intellectual property; and
- The services of Jim Mellon as Executive Director of the Company.
Shellbay shall be entitled to an annual fee equal to the value of 15% of any
increase between the Company's net asset value ("NAV") on a per issued share
basis at the start of a reporting period and 30 June ("Closing NAV Date") each
year during the term of the New Shellbay Agreement, with the first reporting
period being from 1 July 2020 to 30 June 2021, and annually thereafter. The
opening and closing NAV for each period will be based on the audited financial
statements of the Company for the relevant financial year, with the opening
NAV for each reporting period being the higher of (i) 5.86 pence per share
(the highest annual audited NAV per share since the Company adopted its
current investment policy and reported NAV per share in September 2019)), and
(ii) the highest NAV per share reported at a Closing Date for the previous
reporting periods during the term of the agreement (establishing a rolling
high-watermark for Shellbay to qualify for such fee). Any increase in NAV per
share will then be applied to the total issued share capital at the end of the
relevant period for the purposes of determining the 15% fee. Any change in NAV
per share that arises from funds raised at a premium or discount to the
existing NAV per share will therefore be considered for the purposes of
calculating Shellbay's fee by reference to the annual audited accounts (for
clarity being an increase in respect of a premium and a decrease in respect of
a discount).
At the election of the Company, the Shellbay fee shall be payable either in
whole or in part by the issue of new shares at a price equal to the mid-price
on the last day of the relevant Qualifying Period (being the Company's
accounting year from 1 July to 30 June) or grant of nil price warrants over
shares; or in cash; or (with the agreement of Shellbay), in cash-equivalents
(such as shares), and other assets held by the Company.
Shellbay has agreed with the Company that any fee due for the current
reporting period will be settled 50% in cash and 50% in shares (with shares
issued at the mid-market price of Ordinary Shares at close of markets on the
last day of the Qualifying Period, being 30 June 2023).
During the year, a fee of £2,470,600 (30 June 2022: £4,562,548) was accrued
for and recorded in profit and loss. The Shellbay fee is calculated as
follows:
Audited net asset value at 30 June 2022 (post Shellbay fee) £143,912,903
Audited total issued shares at 30 June 2022 969,269,715
Audited net asset value per share at 30 June 2022 14.85 pence
Net asset value at 30 June 2023 (pre Shellbay fee) £169,943,336
Total issued shares at 30 June 2023 993,152,034
Net asset value per share at 30 June 2023 17.11 pence
Increase in net asset value per share 2.26 pence
Increase in net asset value subject to Shellbay fee £22,484,488
───────
15% Shellbay fee based on Net Asset Value per share increase £3,372,672
═══════
At the election of Agronomics, the Shellbay fee will be equally settled by
issuing Agronomics shares and cash. Refer to note 6 and note 9.
3 Net gain/(loss) from financial instruments at fair value
through profit and loss
Derived from financial assets held mandatorily at
fair value through profit or loss at initial recognition:
2023 2022
£ £
Realised gains on sale of investments - 440,322
═══════ ═══════
Unrealised gains on investments 33,585,510 9,655,460
Unrealised losses on investments (3,882,186) (3,671,913)
─────── ───────
Net unrealised gains on investments 29,703,324 5,983,547
═══════ ═══════
Net income from financial instruments at fair value through profit and loss 29,703,324 6,423,869
═══════ ═══════
4 Other operating costs
2023 2022
£ £
Auditors' fees 62,000 81,149
Marketing 148,286 141,083
Professional fees 542,719 1,031,973
Sundry expenses 895,096 499,663
─────── ───────
1,648,101 1,753,868
═══════ ═══════
The Company has no employees.
5 Profit/(loss) from operating activities
Profit/(loss) from operating activities is stated
after charging:
2023 2022
£ £
Auditors' fees 62,000 81,149
Directors' fees 117,709 85,000
═══════ ═══════
6 Share capital, share premium and share reserve
Each share in the Company confers upon the
shareholder:
· the right to one vote at a meeting of the shareholders or on any
resolution of shareholders;
· the right to an equal share in any dividend paid by the Company, and
· the right to an equal share in the distribution of the surplus assets
of the Company on its liquidation.
The Company may by resolution of Directors redeem,
purchase or otherwise acquire all or any of the shares in the Company subject
to regulations set out in the Company's Articles of Association.
2023 2022
£ £
Authorised
2,000,000,000 Ordinary shares of £0.000001 2,000 2,000
════════ ════════
No. of Share Share Share
Shares Capital Premium Reserve
£ £ £
Issued
Balance at 30 June 2021 799,606,383 799 91,278,407 7,394,360
Issued during the year for cash 139,171,126 139 32,044,721 -
Issued during the year to settle share reserve
30,492,206 30 7,394,330 (7,394,360)
Recognition of share reserve - - - 4,341,639
Share issue costs capitalised - - (861,791) -
─────── ─────── ─────── ───────
Balance at 30 June 2022 969,269,715 968 129,855,667 4,341,639
════════ ════════ ════════ ════════
Issued during the year for cash 947,405 1 284,059 -
Issued during the year to settle share reserve 22,934,914 23 4,341,639 (4,341,639)
Recognition of share reserve - - - 1,686,336
─────── ─────── ─────── ───────
Balance at 30 June 2023 993,152,034 992 134,481,365 1,686,336
════════ ════════ ════════ ════════
Capital management
The Company manages its capital to maximise the return to shareholders through
the optimisation of equity. The capital structure of the Company as at 30 June
2023 consists of equity attributable to equity holders of the Company,
comprising issued capital, share premium and accumulated earnings as
disclosed.
The Company manages its capital structure and makes adjustments to it in light
of economic conditions and the strategy approved by shareholders. To maintain
or adjust the capital structure, the Company may make dividend payments to
shareholders, return capital to shareholders or issue new shares and release
the share premium account. No changes were made in the objectives, policies or
processes during the year under review.
Warrants
As part of the fundraise completed during June 2021, the Company issued
warrants attached to the fundraising shares on a 1-for-1 basis, and as such,
297,727,274 warrants were issued to investors who participated in the
fundraise. The warrants are exercisable quarterly over a period of two years,
at a price of 28.5 pence per warrant. The warrants in issue at 30 June 2023
have no dilutive effect on basic earnings per share as the exercise price
exceeds the quoted share price.
As part of the fundraise completed during December 2021, the Company issued
warrants attached to the fundraising shares on a 1-for-1 basis, and as such,
138,368,193 warrants were issued to investors who participated in the
fundraise. The warrants are exercisable quarterly over a period of two years,
at a price of 30 pence per warrant. The warrants in issue at 30 June 2023 have
no dilutive effect on basic earnings per share as the exercise price exceeds
the quoted share price.
Reconciliation of warrants in issue
2023 2022
Number Number
Balance at 1 July 435,292,534 297,727,274
Issued during the year - 138,368,193
Exercised during the year (947,405) (802,933)
─────── ───────
Balance at 30 June 434,345,129 435,292,534
═══════ ═══════
Consulting fee due to Shellbay
As discussed in note 2, a consulting fee due to Shellbay of £3,372,672 has
been recognised (2022: £4,562,548). Shellbay has agreed with the Company that
any fee due for the current reporting period will be settled 50% in cash and
50% in shares (with shares issued at the mid-market price of Ordinary Shares
at close of markets on the last day of the Qualifying Period, being 30 June
2023). As a result, 16,253,847 new ordinary shares (2022: 14,257,963 new
ordinary shares) will be issued to Shellbay at a price of 10.375 pence per
share. A Share Reserve has been recognised relating to these shares to be
issued. The shares to be issued to Shellbay have a dilutive effect on basic
earnings per share. Refer to Note 11.
7 Financial assets at fair value through profit or loss
During 2020, the Company established a wholly owned subsidiary entity,
Agronomics Investment Holdings Limited ("the Subsidiary" or "AIHL"), which
holds the majority of the portfolio of unquoted investments. Unquoted
investments were transferred by the Company into AIHL at their respective
carrying amounts. The investment in subsidiary is stated at fair value through
profit or loss in accordance with the IFRS 10 Investment Entity Consolidation
Exception. The fair value of the investment in subsidiary is based on the
year-end net asset value of the subsidiary. Additions and disposals regarding
the investment in subsidiary are recognised on trade date.
2023 2022
£ £
Quoted 177,330 250,691
Unquoted 7,417,071 6,795,650
Investment in subsidiary 134,178,896 87,766,747
─────── ───────
141,773,297 94,813,088
═══════ ═══════
The composition of the investments held, both directly and indirectly through
the Subsidiary in the underlying portfolio, is as follows:
2023 2022
£ £
Equities 132,664,299 84,942,939
Convertible loan notes and SAFEs* 9,108,998 9,870,149
─────── ───────
141,773,297 94,813,088
═══════ ═══════
* A SAFE is a Simple Agreement for Future Equity. SAFE Agreements have similar
characteristics to Convertible Loans and are designed to provide an early
investor with an "edge" ahead of a larger planned funding. The edge is
typically conversion of funds advanced for new equity at a discount to the
subsequent raise.
These financial instruments were mandatorily held as at fair value through
profit or loss on initial recognition. See note 8 - Fair value of financial
instruments section - regarding the valuation of investments.
8 Financial instruments
Financial Risk Management
The Company has risk management policies that systematically view the risks
that could prevent it from achieving its objectives. These policies are
intended to manage risks identified in such a way that opportunities to
deliver the Company's objectives are achieved. The Company's risk management
takes place in the context of day-to-day operations and normal business
processes such as strategic and business planning. The Directors have
identified each risk and are responsible for coordinating and continuously
improving risk strategies, processes and measures in accordance with the
Company's established business objectives.
The Company's principal financial instruments consist
of investments, cash, receivables and payables arising from its operations and
activities. The main risks arising from the Company's financial instruments
and the policies for managing each of these risks are summarised below.
Credit Risk
Credit risk is the risk of loss associated with the counterparty's inability
to fulfil its obligations. The Company's credit risk is primarily attributable
to receivables, cash balances, and bank deposits, and convertible loan
investments, with the maximum exposure being the reported balance in the
statement of financial position. The Company has a nominal level of debtors
and as such the Company believes that the credit risk to these is minimal. The
Company holds available cash and bank deposits with licensed banks and
financial institutions. The Company considers the credit ratings of banks in
which it holds funds in order to reduce exposure to credit risk. Cash balances
are available on demand, with bank deposits having varying maturities up to 6
months. Convertible loan investments held inherently carry a higher credit
risk, due to the early- stage nature of relevant investee
company.
The carrying amount of financial assets represents the maximum credit
exposure. The maximum exposure to credit risk at the reporting date was:
Carrying amount Carrying amount
2023 2022
£ £
Bank deposits 10,000,000 20,024,175
Cash and cash equivalents 18,093,984 31,458,326
Trade and other receivables 335,810 56,268
Convertible loan investments 7,357,367 6,735,946
─────── ───────
35,787,161 58,274,715
═══════ ═══════
All of cash and cash equivalent and cash deposit balances are held in A+
credit rated financial institutions. The Company considers that ECL exposures
have low credit risk based on the external credit ratings of the financial
institutions.
Market price risk
Market price risk is the risk that the market price will fluctuate due to
macro-economic issues such as changes in market factors specific to that
security, market interest rates and foreign exchange rates.
The Company is exposed to significant market price risks as financial
instruments recognised directly by the Company and indirectly by the
Subsidiary are linked to market price volatility.
A 10% increase/decrease in market value of investments held by the Company and
its subsidiary would increase/decrease equity and profit by £13,575,948
(2022: £9,481,309).
Liquidity risk
The Company is exposed to liquidity risk to the
extent that it holds investments that it may not be able to sell quickly at
close to fair value.
The risk is managed by the Company by means of cash flow planning to ensure
that future cash requirements are anticipated and, where financial instruments
have to be sold to meet these requirements, the process is carried out in a
controlled manner intended to minimise the liquidity risk involved.
The residual undiscounted contractual maturities of financial liabilities and
financial assets are as follows:
30 June 2023 Less than 1 month 1-3 months 3 months to 1 year 1-5 years Over 5 years No stated maturity Total
£ £ £ £ £ £
Financial liabilities
Trade and other payables 202,269 - 1,686,336 - - - 1,888,605
30 June 2022
Trade and other payables 204,071 - 2,281,274 - - - 2,485,345
30 June 2023
Financial assets
Financial assets at fair value through profit or loss - - - - - 134,415,930 134,415,930
Bank deposits - 10,000,000 - - - - 10,000,000
Cash and cash equivalents 18,093,984 - - - - - 18,093,984
Trade and other receivables 335,810 - - - - - 335,810
Convertible loan investments - - 7,357,367 - - - 7,357,367
18,429,794 10,000,000 7,357,367 - - 134,415,930 170,203,091
30 June 2022
Financial assets at fair value through profit or loss - - - - - 88,077,142 88,077,142
Bank deposits 10,024,175 - 10,000,000 - - - 20,024,175
Cash and cash equivalents 23,458,326 8,000,000 - - - - 31,458,326
Trade and other receivables 56,268 - - - - - 56,268
Convertible loan investments - - - 6,735,946 - - 6,735,946
33,538,769 8,000,000 10,000,000 6,735,946 - 88,077,142 146,351,857
Interest rate risk
A significant share of the Company's assets is comprised of cash held at
banks. As a result, the Company is subject to risk due to fluctuations in the
prevailing level of market interest rates. However, income earned from bank
interest is not considered material to the Company's performance or financial
position.
The Company holds investments in convertible loan notes ("CLN"), which attract
interest income. The rates of interest are fixed for each CLN investment held,
which results in a reduced interest rate risk.
Fair values of financial assets and liabilities
At 30 June 2023, the carrying amounts of cash resources, trade and other
receivables, and trade and other payables approximate fair value due to their
short-term maturities.
Foreign currency risk
The Company is exposed to foreign currency risk on fluctuations related to
financial assets and liabilities held directly itself and indirectly via its
subsidiary that are denominated in a number of currencies. The Investment in
Subsidiary is held in Sterling. The analysis below reflects the underlying
currency exposure in the Subsidiary's portfolio.
GBP equivalents as at 30 June 2023
Financial assets at fair value through profit and loss Cash at bank Total by currency
£ £ £
USD 83,763,337 2,775,217 86,538,554
EUR 38,140,843 - 38,140,843
AUD 9,214,471 2,057 9,216,528
─────── ─────── ───────
131,118,651 2,777,274 133,895,925
═══════ ═══════ ═══════
GBP equivalents as at 30 June 2022
Financial assets at fair value through profit and loss Cash at bank Total by currency
£ £ £
USD 65,031,554 81,983 65,113,537
EUR 28,898,815 - 28,898,815
─────── ─────── ───────
93,930,369 81,983 94,012,352
═══════ ═══════ ═══════
The following significant exchange rates applied during the year:
Average Average
rate for rate for
active year active year
2023 2022
USD 1.20600 1.33208
EUR 1.14918 1.18085
AUD 1.79225 -
Year-end Year-end
rate rate
2023 2022
USD 1.26281 1.21780
EUR 1.16525 1.16170
AUD 1.88122 -
Sensitivity analysis
A 10% percent strengthening of Sterling against the relevant currencies above
at 30 June 2023, and 10% at 30 June 2022, would have decreased equity and
profit for the year by the amounts shown below. The analysis assumes that all
other variables, in particular interest rates, remain constant.
2023 Equity and Profit or loss
£
USD 8,653,855
EUR 3,814,084
AUD 921,653
2022 Equity and Profit or loss
£
USD 6,511,354
EUR 2,889,882
A 10% percent weakening of Sterling against the relevant currencies above at
30 June 2023, and 10% at 30 June 2022, would have the equal but opposite
effect on the basis that all other variables, in particular interest rates,
remain constant.
Fair value of financial instruments
The fair values of financial assets and financial liabilities that are traded
in an active market are based on quoted market prices. For all other financial
instruments, the Company and its subsidiary determine fair values using other
valuation techniques in compliance with IFRS9: Financial Instruments, IFRS13:
Fair Value Measurement, and based on the International Private Equity and
Venture Capital Valuation Guidelines ("IPEV").
For financial instruments that trade infrequently and have little price
transparency, fair value is less objective, and requires varying degrees of
judgement depending on liquidity, uncertainty of market factors, pricing
assumptions and other risks affecting the specific instrument.
The Company measures fair values using the following fair value hierarchy that
reflects the significance of the inputs used in making the measurements:
· Level 1: Inputs that are quoted market prices (unadjusted) in
active markets for identical instruments;
· Level 2: Inputs other than quoted prices included within Level 1
that are observable either directly (i.e. as prices) or indirectly (i.e.
derived from prices). This category includes instruments valued using; quoted
market prices in active markets for similar instruments; quoted prices for
identical or similar instruments in markets that are considered less than
active; or other valuation techniques in which all significant inputs are
directly or indirectly observable from market data;
· Level 3: Inputs that are unobservable. This category includes all
instruments for which the valuation technique includes inputs not based on
observable data and the unobservable inputs have a significant effect on the
instrument's valuation. This category includes instruments that are valued
based on quoted prices for similar instruments but for which significant
unobservable adjustments or assumptions are required to reflect differences
between the instruments.
Various valuation techniques may be applied in determining the fair value of
investments held as Level 3 in the fair value hierarchy. The objective of
valuation techniques is to arrive at a fair value measurement that reflects
the price that would be received to sell the asset or paid to transfer the
liability in an orderly transaction between market participants at the
measurement date.
Fair value hierarchy measurement at 30 June 2023
Investments in securities at fair value:
Quoted prices Significant other Significant
In active markets observable unobservable
for identical inputs Inputs
assets
Total (Level 1) (Level 2)
(Level 3)
Investments
Quoted 177,330 177,330 - -
Unquoted 7,417,071 - - 7,417,071
Investment in subsidiary 134,178,896 - - 134,178,896
─────── ─────── ─────── ───────
141,773,297 177,330 - 141,595,967
═══════ ═══════ ═══════ ═══════
The investment in subsidiary held by the Company is classified as level 3 in
the fair value hierarchy - being based on the net asset value of the
Subsidiary. All the underlying investments held by the Subsidiary are classed
as level 3 investments.
Reconciliation of Level 3 investments:
Opening balance at 1 July 2022 94,562,397
Purchases 19,542,137
Unrealised foreign currency loss (2,729,121)
Unrealised fair value gain 33,556,823
Unrealised fair value loss (3,780,138)
Accrued interest on loan note investments 443,869
───────
Closing balance at 30 June 2023 141,595,967
═══════
Fair value hierarchy measurement at 30 June 2022
Investments in securities at fair value:
Quoted prices Significant other Significant
In active markets observable unobservable
for identical inputs Inputs
assets
Total (Level 1) (Level 2)
(Level 3)
Investments
Quoted 250,691 250,691 - -
Unquoted 6,795,650 - - 6,795,650
Investment in subsidiary 87,766,747 87,766,747
─────── ─────── ─────── ───────
94,813,088 250,691 - 94,562,397
═══════ ═══════ ═══════ ═══════
The investment in subsidiary held by the Company is classified as level 3 in
the fair value hierarchy - being based on the net asset value of the
Subsidiary. All the underlying listed equity investments held by the
Subsidiary are classed as level 3 investments
Reconciliation of Level 3 investments:
Opening balance at 1 July 2021 38,126,352
Purchases 44,092,779
Disposals (256,133)
Unrealised foreign currency gain 5,940,553
Unrealised fair value gain 9,655,460
Unrealised fair value loss (3,280,099)
Accrued interest on loan note investments 283,485
───────
Closing balance at 30 June 2022 94,562,397
═══════
Valuation technique
In the absence of observable prices or suitable unobservable model inputs
being available and, given level 3 portfolio companies are in the
start-up/development stage and in the biotechnology/ biopharmaceutical sector,
the Board believes that a recent share transaction cost represents the best
available estimate of fair value. The price of a recent investment valuation
technique, calibrated using both financial and technological milestones, is
commonly used in a seed, start-up or early-stage situations. Where applicable,
the Company's Level 3 investments are valued at the price of each funding
round of the respective companies entered into with their shareholders,
adjusted where necessary should the Directors deem any adjustment is needed in
order to determine the fair value. The fair value of the relevant investee may
also be adjusted based on its performance against predetermined milestones.
The Directors deem all investments to be held at fair value. The price of a
recent transaction is deemed most appropriate for the Company's and
Subsidiary's unquoted investments. Although the Board believes that its
estimates of fair value are appropriate, the use of different methodologies or
assumptions could lead to different measurements of fair value. The Board
continues to monitor the performance of the investee entities and the
underlying information available in order to assess whether the valuation
technique adopted and the fair value hierarchy remain appropriate.
No reasonably possible alternative assumptions
IFRS 13 requires disclosure, by class of financial instrument, if the effect
of changing one or more inputs to reasonably possible alternative assumptions
would result in a significant change to the fair value measurement. However,
where fair value is determined with reference to the price of a recent
transaction in the equity shares of the unquoted company, such a sensitivity
analysis is not relevant. As such the Directors consider there are no
reasonably possible alternative assumptions in respect of the level 3
investments held at year end.
The valuation approach adopted for the years ended 30 June 2023 and 30 June
2022 is consistent.
9 Trade and other payables
2023 2022
£ £
Provision for audit fee 57,488 55,000
Trade creditors 202,269 149,071
Provision for Shellbay fee (note 2) 1,686,336 2,281,274
────── ──────
1,946,093 2,485,345
══════ ══════
As disclosed in Note 2, the Shellbay fee recognised during the year will be
settled partly in cash totalling £1,686,336 (2022: £2,281,274).
10 Related party transactions
Under an agreement dated 1 December 2011, Burnbrae Limited, a Company for
which Jim Mellon is the ultimate beneficial owner and Denham Eke is a
Director, provide certain services, principally accounting and administration,
to the Company. This agreement may be terminated by either party on three
months' notice. The charge for services provided in the year in accordance
with the contract was £30,000 (2022: £31,500) of which £3,000 was
outstanding as at the year-end (2022: £3,000).
Under an updated agreement dated May 2021, Shellbay Investments Limited, a
Company related to both Jim Mellon and Denham Eke, provides certain services
to the Company (see note 2). The charge for services provided in the year was
£3,372,672 (2022: £4,562,548), with the Company opting to settle the fee
50/50 in cash and Agronomics shares.
In accordance with the published investing policy, Jim Mellon holds personal
interests both directly and indirectly in the following investee companies:
AgeX Therapeutics Inc, Endurance RP, Portage Biotech Inc, SalvaRX Group PLC,
Cytox Limited, Simply Foods Inc, Shiok Meats Pte. Ltd, Good Dog Food Ltd and
Bond Pets LLC.
Edgewater Associates Limited ("Edgewater")
During the year, Directors and Officers insurance was obtained through
Edgewater, which is a 100% subsidiary of Manx Financial Group ("MFG"). Jim
Mellon and Denham Eke are Directors of MFG and Denham Eke is a Director of
Edgewater.
The annual policy premium was £42,000 (2022: £19,500), and £nil was
outstanding as at year-end (2022: £nil).
11 Basic and diluted earnings per share
The calculation of the basic earnings per share is based on the earnings
attributable to ordinary shareholders divided by the weighted average number
of shares in issue during the year.
The calculation of diluted earnings per share is based on the basic earnings
per share, adjusted to allow for the issue of shares, on the assumed
conversion of all dilutive share options.
2023 2022
£ £
Profit for the year 22,373,676 8,358,379
No. No.
Weighted average number of ordinary shares in issue 984,863,129 877,490,411
Dilutive effect of shares to be issued (Note 6) 32,507,695 37,192,877
Diluted number of ordinary shares 1,017,370,824 914,683,288
Basic earnings per share (pence) 2.27 0.95
Diluted earnings per share (pence) 2.20 0.91
12 The Subsidiary
The Company has one wholly owned subsidiary entity, Agronomics Investment
Holdings Limited, which is incorporated in the British Virgin Islands. The
Subsidiary was incorporated on 8 July 2020 under the provisions of the BVI
Business Companies Act, 2004, as a limited liability company. The principal
activity of the Subsidiary is holding investments on behalf of the Company.
13 Subsequent events
Post yearend, the Company received warrant exercise notices and issued a total
of 2,210 Ordinary Shares, for cash proceeds of £659.
On 22 September 2023, the Company announced that it will execute an on-market
Share buyback programme for an aggregate amount of up to £3 million. The
term of the buyback programme shall be 6 months, commencing on
2 October 2023. To date, no buybacks have been executed as the Company
remains in a closed period under AIM rules.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END FR UUVNROUUUUAARecent news on Agronomics
See all newsRCS - Agronomics Limited - BlueNalu Expands Partnership with Nomad Foods
AnnouncementRCS - Agronomics Limited - Liberation Labs secures strategic partnership
AnnouncementREG - Agronomics Limited - Exercise of Shellbay options
AnnouncementREG - Agronomics Limited - Unaudited Interim Results
AnnouncementRCS - Agronomics Limited - Solar Foods Secures €10 million Grant
Announcement